US7138486B2
(en)
*
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
US6849708B1
(en)
|
1986-05-05 |
2005-02-01 |
The General Hospital Corporation |
Insulinotropic hormone and uses thereof
|
US5614492A
(en)
*
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
ES2319936T5
(es)
*
|
1996-08-08 |
2013-06-24 |
Amylin Pharmaceuticals, Inc. |
Regulación de la motilidad gastrointestinal
|
WO1998030231A1
(en)
|
1997-01-07 |
1998-07-16 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the reduction of food intake
|
US5846937A
(en)
*
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
US7157555B1
(en)
*
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
EP1066314B1
(de)
|
1997-11-14 |
2007-12-26 |
Amylin Pharmaceuticals, Inc. |
Neuartige exendin agonisten
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
KR100637433B1
(ko)
*
|
2004-05-24 |
2006-10-20 |
삼성에스디아이 주식회사 |
발광 표시 장치
|
WO1999043705A1
(en)
*
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
EP1306091A3
(de)
|
1998-07-31 |
2003-05-21 |
Novo Nordisk A/S |
Stimulation der Beta-Zellen Vermehrung
|
US6720407B1
(en)
*
|
1998-08-28 |
2004-04-13 |
Eli Lilly And Company |
Method for administering insulinotropic peptides
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
US7259136B2
(en)
*
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
WO2000034331A2
(en)
|
1998-12-07 |
2000-06-15 |
Societe De Conseils De Recherches Et D'applications Scientifiques Sas |
Analogues of glp-1
|
US7919109B2
(en)
|
1999-02-08 |
2011-04-05 |
Intarcia Therapeutics, Inc. |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
ATE509028T1
(de)
|
1999-03-15 |
2011-05-15 |
Novo Nordisk As |
Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
|
US6605648B1
(en)
*
|
1999-04-06 |
2003-08-12 |
Phillips Plastics Corporation |
Sinterable structures and method
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
WO2000069911A1
(en)
|
1999-05-17 |
2000-11-23 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
WO2001000654A2
(en)
|
1999-06-29 |
2001-01-04 |
Pharmaceutical Discovery Corporation |
Purification and stabilization of peptide and proteins in pharmaceutical agents
|
US9006175B2
(en)
*
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
US6844321B2
(en)
|
2000-01-31 |
2005-01-18 |
Novo Nordisk A/S |
Crystallization of a GLP-1 analogue
|
WO2001066135A1
(en)
|
2000-03-08 |
2001-09-13 |
Novo Nordisk A/S |
Lowering serum lipids
|
AU2001259063A1
(en)
|
2000-04-12 |
2001-10-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2002224124A1
(en)
|
2000-12-01 |
2002-06-11 |
Takeda Chemical Industries Ltd. |
Method for producing preparation containing bioactive substance
|
WO2002085406A1
(en)
*
|
2001-04-24 |
2002-10-31 |
Restoragen, Inc. |
Methods and compositions for treating conditions associated with insulin resistance
|
AU2002317599B2
(en)
*
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
US6642003B2
(en)
|
2001-08-02 |
2003-11-04 |
Cedars-Sinai Medical Center |
Human glucose-dependent insulin-secreting cell line
|
WO2003059934A2
(en)
*
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1463751B1
(de)
|
2001-12-21 |
2013-05-22 |
Human Genome Sciences, Inc. |
Albuminfusionsproteine
|
US7141240B2
(en)
*
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
DE60318938T2
(de)
|
2002-03-20 |
2009-01-22 |
Mannkind Corp., Valencia |
Inhalationsgerät
|
US20080260838A1
(en)
*
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
US20040209803A1
(en)
*
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
US7790681B2
(en)
*
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
EP1594530A4
(de)
|
2003-01-22 |
2006-10-11 |
Human Genome Sciences Inc |
Albuminfusionsproteine
|
EP1617888B1
(de)
|
2003-04-23 |
2019-06-12 |
Valeritas, Inc. |
Hydraulisch aktivierte pumpe für langzeitabgabe von medikamenten
|
WO2005000222A2
(en)
|
2003-05-30 |
2005-01-06 |
Amylin Pharmaceuticals, Inc. |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
EP1664108B1
(de)
|
2003-08-21 |
2009-10-14 |
Novo Nordisk A/S |
Trennung von polypeptiden mit einer racemisierten aminosäure
|
WO2005021026A2
(en)
*
|
2003-08-29 |
2005-03-10 |
Amylin Pharmaceuticals, Inc. |
Methods for treating or ameliorating ghrelin-associated diseases and disorders
|
KR101243648B1
(ko)
|
2003-11-20 |
2013-03-14 |
노보 노르디스크 에이/에스 |
제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
|
EP1694356B1
(de)
|
2003-12-09 |
2011-02-16 |
Novo Nordisk A/S |
Regulierung der nahrungspräferenz mit glp-1-agonisten
|
EP1701731A4
(de)
*
|
2003-12-12 |
2009-08-05 |
Einstein Coll Med |
Glp-1 (9-36) verfahren und zusammensetzungen
|
US20080194483A1
(en)
*
|
2003-12-12 |
2008-08-14 |
Brownlee Michael A |
GLP-1 (9-36) methods and compositions
|
JP2007514752A
(ja)
|
2003-12-16 |
2007-06-07 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1医薬組成物
|
JP2007536214A
(ja)
|
2003-12-16 |
2007-12-13 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1類似体
|
EP1729795B1
(de)
*
|
2004-02-09 |
2016-02-03 |
Human Genome Sciences, Inc. |
Albuminfusionsproteine
|
DE602005022239D1
(de)
*
|
2004-04-23 |
2010-08-19 |
Conjuchem Biotechnologies Inc |
Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
WO2005120492A1
(en)
|
2004-06-11 |
2005-12-22 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
US9089636B2
(en)
|
2004-07-02 |
2015-07-28 |
Valeritas, Inc. |
Methods and devices for delivering GLP-1 and uses thereof
|
EP1786784B1
(de)
|
2004-08-20 |
2010-10-27 |
MannKind Corporation |
Katalyse der diketopiperazinsynthese
|
CA2578175C
(en)
|
2004-08-23 |
2014-10-14 |
Mannkind Corporation |
Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US7803404B2
(en)
|
2005-09-14 |
2010-09-28 |
Mannkind Corporation |
Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
WO2007064757A1
(en)
*
|
2005-11-29 |
2007-06-07 |
University Of Florida Research Foundation, Inc. |
Anti-thymocyte globulin to prevent or delay the onset or the progression on type 1 diabetes
|
EP2364735A3
(de)
|
2005-12-16 |
2012-04-11 |
Nektar Therapeutics |
Verzweigte PEG-Kon jugate von GLP-1
|
CN101379075B
(zh)
|
2006-02-08 |
2013-05-15 |
隆萨股份公司 |
类胰高血糖素肽的合成
|
BRPI0707991B8
(pt)
|
2006-02-22 |
2021-05-25 |
Mannkind Corp |
métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
|
ES2566058T3
(es)
|
2006-03-30 |
2016-04-08 |
Valeritas, Inc. |
Dispositivo de suministro de fluidos de múltiples cartuchos
|
DE602007009377D1
(de)
|
2006-05-30 |
2010-11-04 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
US7682356B2
(en)
|
2006-08-09 |
2010-03-23 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies for use therein
|
JP5351884B2
(ja)
|
2007-04-23 |
2013-11-27 |
インターシア セラピューティクス,インコーポレイティド |
インスリン分泌促進性ペプチドの懸濁製剤及び使用
|
EP2185689A2
(de)
|
2007-08-09 |
2010-05-19 |
Genzyme Corporation |
Verfahren zur behandlung von autoimmunerkrankungen mit mesenchymalen stammzellen
|
US8758761B2
(en)
*
|
2007-09-30 |
2014-06-24 |
University Of Florida Research Foundation, Inc. |
Combination therapies for treating type 1 diabetes
|
JP5813323B2
(ja)
*
|
2007-10-24 |
2015-11-17 |
マンカインド コーポレイション |
活性薬剤の送達方法
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
CN101969927A
(zh)
*
|
2007-10-24 |
2011-02-09 |
曼金德公司 |
预防glp-1不良影响的方法
|
EP2231191A2
(de)
*
|
2007-12-11 |
2010-09-29 |
ConjuChem Biotechnologies Inc. |
Formulierung von insulinotropen peptid-konjugaten
|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
EP2570147B1
(de)
|
2008-06-13 |
2017-10-18 |
MannKind Corporation |
Trockenpulverinhalator und System zur Wirkstofffreisetzung
|
US9364619B2
(en)
|
2008-06-20 |
2016-06-14 |
Mannkind Corporation |
Interactive apparatus and method for real-time profiling of inhalation efforts
|
TWI614024B
(zh)
|
2008-08-11 |
2018-02-11 |
曼凱公司 |
超快起作用胰島素之用途
|
WO2010054326A2
(en)
|
2008-11-07 |
2010-05-14 |
The General Hospital Corporation |
C-terminal fragments of glucagon-like peptide-1 (glp-1)
|
EP2373391A1
(de)
|
2008-12-08 |
2011-10-12 |
Novo Nordisk A/S |
Gegenstromreinigung von polypeptiden
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
PL2405963T3
(pl)
|
2009-03-11 |
2014-04-30 |
Mannkind Corp |
Urządzenie, układ i sposób pomiaru oporu inhalatora
|
KR20180079458A
(ko)
|
2009-06-12 |
2018-07-10 |
맨카인드 코포레이션 |
한정된 비표면적을 갖는 디케토피페라진 마이크로입자
|
HUE035862T2
(en)
|
2009-09-28 |
2018-05-28 |
Intarcia Therapeutics Inc |
Rapid development and / or completion of substantially steady-state drug delivery
|
EP2496295A1
(de)
|
2009-11-03 |
2012-09-12 |
MannKind Corporation |
Vorrichtung und verfahren zur simulation von einatmungsanstrengungen
|
CA2782056C
(en)
|
2009-11-25 |
2021-03-09 |
Arisgen Sa |
Mucosal delivery of peptides
|
EP2555791B1
(de)
|
2010-04-09 |
2017-11-01 |
Sinai Health System |
Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten
|
CA2797033C
(en)
|
2010-04-22 |
2021-10-19 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
RU2531455C2
(ru)
|
2010-06-21 |
2014-10-20 |
Маннкайнд Корпорейшн |
Системы и способы доставки сухих порошковых лекарств
|
EP2588490B1
(de)
|
2010-07-02 |
2017-02-22 |
Angiochem Inc. |
Kurze und d-aminosäure-haltige polypeptide für therapeutische konjugate und ihre verwendungen
|
WO2012054822A1
(en)
|
2010-10-22 |
2012-04-26 |
Nektar Therapeutics |
Pharmacologically active polymer-glp-1 conjugates
|
WO2012054861A1
(en)
|
2010-10-22 |
2012-04-26 |
Nektar Therapeutics |
Glp-1 polymer conjugates having a releasable linkage
|
WO2012061466A2
(en)
|
2010-11-02 |
2012-05-10 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
CN105667994B
(zh)
|
2011-04-01 |
2018-04-06 |
曼金德公司 |
用于药物药盒的泡罩包装
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
WO2013006692A2
(en)
|
2011-07-06 |
2013-01-10 |
The General Hospital Corporation |
Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
|
AU2012328885B2
(en)
|
2011-10-24 |
2017-08-31 |
Mannkind Corporation |
Methods and compositions for treating pain
|
CN104582736A
(zh)
|
2012-06-21 |
2015-04-29 |
印第安纳大学研究及科技有限公司 |
Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物
|
JP6224586B2
(ja)
|
2012-07-10 |
2017-11-01 |
武田薬品工業株式会社 |
注射用製剤
|
CN108057154B
(zh)
|
2012-07-12 |
2021-04-16 |
曼金德公司 |
干粉药物输送系统和方法
|
US10159644B2
(en)
|
2012-10-26 |
2018-12-25 |
Mannkind Corporation |
Inhalable vaccine compositions and methods
|
CA2906817C
(en)
|
2013-03-15 |
2022-01-18 |
Mannkind Corporation |
Microcrystalline diketopiperazine compositions and methods
|
US9789164B2
(en)
|
2013-03-15 |
2017-10-17 |
Longevity Biotech, Inc. |
Peptides comprising non-natural amino acids and methods of making and using the same
|
US9925144B2
(en)
|
2013-07-18 |
2018-03-27 |
Mannkind Corporation |
Heat-stable dry powder pharmaceutical compositions and methods
|
JP2016530930A
(ja)
|
2013-08-05 |
2016-10-06 |
マンカインド コーポレイション |
通気装置及び方法
|
CN106029087A
(zh)
|
2013-12-20 |
2016-10-12 |
印第安纳大学研究及科技有限公司 |
脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
CN104267194B
(zh)
*
|
2014-09-23 |
2016-01-13 |
上海市东方医院 |
人胰高血糖素样肽-1、抗体及其试剂盒
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
ES2968262T3
(es)
|
2015-06-03 |
2024-05-08 |
I2O Therapeutics Inc |
Sistemas de colocación de implantes
|
WO2017200943A1
(en)
|
2016-05-16 |
2017-11-23 |
Intarcia Therapeutics, Inc. |
Glucagon-receptor selective polypeptides and methods of use thereof
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
CN110225762A
(zh)
|
2017-01-03 |
2019-09-10 |
因塔西亚制药公司 |
包括glp-1受体激动剂的连续施用和药物的共同施用的方法
|
HRP20240485T1
(hr)
|
2017-08-24 |
2024-07-05 |
Novo Nordisk A/S |
Pripravci glp-1 i njihova upotreba
|
WO2020077129A1
(en)
|
2018-10-11 |
2020-04-16 |
Intarcia Therapeutics, Inc. |
Human amylin analog polypeptides and methods of use
|
US20230082544A1
(en)
|
2020-02-18 |
2023-03-16 |
Novo Nordisk A/S |
Pharmaceutical formulations
|
CA3223596A1
(en)
*
|
2021-06-29 |
2023-01-05 |
Thomas A. GILL |
Peptides for regulating glucose
|